Dss's impact biomedical receives notice of allowance from uspto for equivir patent

Rochester, n.y., april 06, 2021 (globe newswire) -- document security systems, inc. (“dss” or the “company”) (nyse american: dss), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary impact biomedical, inc. (“impact biomedical”) received notice of allowance (us 16/544,308) from the u.s. patent and trademark office (“uspto”) for a method of limiting the occurrence of, reducing the risk or severity of, or treating ebola and rhinovirus using its proprietary equivir compound.   this allowance is in addition to equivir's previously issued u.s. patent in influenza.
DSS Ratings Summary
DSS Quant Ranking